

# Elisabetta Antonelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6929536/publications.pdf>

Version: 2024-02-01

55  
papers

4,017  
citations

182225

30  
h-index

198040

52  
g-index

56  
all docs

56  
docs citations

56  
times ranked

5314  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dermatological Manifestations in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 364.	1.0	42
2	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
3	Inhibitors of the Janus Kinases. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 635-640.	1.1	5
4	Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. <i>Annals of Diagnostic Pathology</i> , 2019, 38, 20-25.	0.6	7
5	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018, 50, 734-736.	0.4	3
6	Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. <i>Techniques in Coloproctology</i> , 2018, 22, 941-946.	0.8	13
7	Novel oral-targeted therapies for mucosal healing in ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 5322-5330.	1.4	28
8	Eosinophilia " associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. <i>Apmis</i> , 2017, 125, 179-183.	0.9	12
9	Enteric glial cells are susceptible to Clostridium difficile toxin B. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1527-1551.	2.4	37
10	Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study. <i>Scientific Reports</i> , 2017, 7, 6839.	1.6	19
11	Assessing mucosal healing in ulcerative colitis: the simpler, the better". <i>Endoscopy</i> , 2015, 47, 759-759.	1.0	4
12	Is It Possible to Identify Patients With Inflammatory Bowel Disease Who Are at Risk for Cytomegalovirus Infection?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 138-139.	2.4	0
13	The importance of histologic parameters of lacteal involvement in cases of canine lymphoplasmacytic enteritis. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015, 8, 33-41.	0.6	8
14	Gastrointestinal motility disorders in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 37.	1.4	72
15	Colonic motility in ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2014, 2, 457-462.	1.6	34
16	Endoscopic biopsy samples of naïve "œcolitides" patients: Role of basal plasmacytosis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1438-1443.	0.6	28
17	The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. <i>International Journal of Colorectal Disease</i> , 2013, 28, 267-272.	1.0	19
18	Definition and evaluation of mucosal healing in clinical practice. <i>Digestive and Liver Disease</i> , 2013, 45, 969-977.	0.4	107

#	ARTICLE	IF	CITATIONS
19	Pseudomembranous collagenous colitis with superimposed drug damage. <i>Pathology Research and Practice</i> , 2013, 209, 735-739.	1.0	15
20	Prevalence and causes of abnormal liver function in patients with coeliac disease. <i>Liver International</i> , 2013, 33, 1128-1131.	1.9	20
21	Histological healing in inflammatory bowel disease: A still unfulfilled promise. <i>World Journal of Gastroenterology</i> , 2013, 19, 968.	1.4	87
22	Papillary thyroid cancer and ulcerative colitis. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 52-4.	0.6	5
23	Increase of Colonic Mast Cells in Obstructed Defecation and Their Relationship with Enteric Glia. <i>Digestive Diseases and Sciences</i> , 2012, 57, 65-71.	1.1	24
24	Intestinal superinfections in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 154-159.	0.6	48
25	Ultrasonographic assessment of colonic wall in moderate to severe ulcerative colitis: Comparison with endoscopic findings. <i>Digestive and Liver Disease</i> , 2011, 43, 703-706.	0.4	39
26	Non-IBD colitides: clinically useful histopathological clues. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 366-372.	0.1	15
27	Gastrointestinal Foxp3 expression in normal, inflammatory and neoplastic conditions. <i>Pathology</i> , 2011, 43, 465-471.	0.3	3
28	Successful twin pregnancy in a patient with ulcerative colitis using azathioprine during conception. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2011, 4, 224-7.	0.6	0
29	Inflammatory bowel disease in the dog: Differences and similarities with humans. <i>World Journal of Gastroenterology</i> , 2010, 16, 1050.	1.4	102
30	Pulmonary diseases associated with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 384-389.	0.6	37
31	Enteric neuroglial apoptosis in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 264-270.	0.6	34
32	A Simplified Method for Anal Ultrasonography. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 453-456.	1.1	1
33	The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 327-330.	0.6	18
34	Enteric glial cells: new players in gastrointestinal motility?. <i>Laboratory Investigation</i> , 2007, 87, 628-632.	1.7	95
35	Enteric glial cells and their role in gastrointestinal motor abnormalities: Introducing the neuro-gliopathies. <i>World Journal of Gastroenterology</i> , 2007, 13, 4035.	1.4	63
36	Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 325-335.	1.3	238

#	ARTICLE	IF	CITATIONS
37	Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor $\beta$ 3 Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 58-68.	1.3	169
38	The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. <i>Hepatology</i> , 2005, 42, 539-548.	3.6	504
39	Dual COX-Inhibitors: The Answer is NO?. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 487-492.	1.0	8
40	A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 584-595.	1.3	176
41	The Methyl Transferase PRMT1 Functions as Co-Activator of Farnesoid X Receptor (FXR)/9-cis Retinoid X Receptor and Regulates Transcription of FXR Responsive Genes. <i>Molecular Pharmacology</i> , 2005, 68, 551-558.	1.0	74
42	Inhibition of Hydrogen Sulfide Generation Contributes to Gastric Injury Caused by Anti-Inflammatory Nonsteroidal Drugs. <i>Gastroenterology</i> , 2005, 129, 1210-1224.	0.6	367
43	Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 604-612.	1.3	190
44	PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. <i>Hepatology</i> , 2004, 39, 365-375.	3.6	149
45	The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. <i>Gastroenterology</i> , 2004, 127, 1497-1512.	0.6	406
46	Treatment of Portal Hypertension with NCX-1000, a Liver-Specific NO donor. A Review of Its Current Status. <i>Cardiovascular Drug Reviews</i> , 2004, 22, 135-146.	4.4	21
47	NCX-1000: a liver-specific NO donor. , 2004, , 105-110.		0
48	The FXR-agonist, 6-ethyl-chenodeoxycholic acid (6-ECDCA), protects against estrogen-induced cholestasis in rats. <i>Gastroenterology</i> , 2003, 124, A698.	0.6	1
49	NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. <i>Journal of Hepatology</i> , 2003, 39, 932-939.	1.8	77
50	Nonlinear partial differential equations and applications: NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 15770-15775.	3.3	72
51	A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway – THIS ARTICLE HAS BEEN RETRACTED. <i>British Journal of Pharmacology</i> , 2002, 135, 589-599.	2.7	31
52	Nitric Oxide-Releasing NSAIDs. <i>Drug Safety</i> , 2001, 24, 801-811.	1.4	74
53	NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8897-8902.	3.3	128
54	NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. <i>Gastroenterology</i> , 2000, 118, 404-421.	0.6	104

#	ARTICLE	IF	CITATIONS
55	Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. <i>Gastroenterology</i> , 1999, 116, 1089-1106.	0.6	148